1,552 results match your criteria Metastatic Cancer Unknown Primary Site


Primary cystic neuroendocrine tumor of the liver: case report

Rev Med Inst Mex Seguro Soc 2019 Jan 28;56(5):505-509. Epub 2019 Jan 28.

Instituto Mexicano del Seguro Social, Hospital de Especialidades "Dr. Bernardo Sepúlveda Gutiérrez", Servicio de Anatomía Patológica. Ciudad de México, México

Background: 85% of neuroendocrine tumors (NET) originate in the gastrointestinal tract, which is why their primary hepatic location is very rare; NETs most frequently cause metastases to the liver; so when diagnosed, a hepatic NET is considered initially metastatic. Diagnosis of primary hepatic neuroendocrine tumors (PHNET) should be performed by excluding extrahepatic NETs and through histological confirmation. The objective of this article is to present a case of PHNET. Read More

View Article

Download full-text PDF

Source
January 2019

Does Resection of the Primary Tumor Improve Survival in Patients With Metastatic Chondrosarcoma?

Clin Orthop Relat Res 2019 Mar;477(3):573-583

K. Song, J. Song, F. Chen, X. Ma, J. Jiang, Department of Orthopaedics, Huashan Hospital, Fudan University, Shanghai, China K. Lin, Department of Orthopaedics, Zhongshan Hospital, Fudan University, Shanghai, China The first two authors contributed equally to this manuscript.

Background: Although surgical resection or amputation has been the mainstay of localized chondrosarcoma management for many decades, its efficacy in patients with metastatic chondrosarcoma remains unknown, and likewise we do not know whether there are any tumor- or patient-related factors associated with better survival after surgery for metastatic chondrosarcoma.

Questions/purposes: (1) Is resection of the primary tumor associated with improved survival in patients with metastatic chondrosarcoma? (2) Which subgroups of patients with chondrosarcoma benefit more from resection in terms of survival?

Methods: We identified 200 of 222 patients with metastatic chondrosarcoma in the Surveillance, Epidemiology, and End Results (SEER) database between 1988 and 2014 based on the exclusion criteria. Among those patients, 107 (53. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CORR.0000000000000632DOI Listing

Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.

BMC Cancer 2019 Jan 14;19(1):67. Epub 2019 Jan 14.

Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Department of Bioinformatics, Fujian Medical University, Fuzhou, 350001, China.

Background: Precise diagnosis of the tissue origin for metastatic cancer of unknown primary (CUP) is essential for deciding the treatment scheme to improve patients' prognoses, since the treatment for the metastases is the same as their primary counterparts. The purpose of this study is to identify a robust gene signature that can predict the origin for CUPs.

Methods: The within-sample relative gene expression orderings (REOs) of gene pairs within individual samples, which are insensitive to experimental batch effects and data normalizations, were exploited for identifying the prediction signature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5274-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332677PMC
January 2019
3 Reads

Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.

Scand J Gastroenterol 2019 Jan 13:1-7. Epub 2019 Jan 13.

a Department of Internal Medicine, Division of Gastroenterology , Landspitali University Hospital , Reykjavik , Iceland.

Objective: To determine the incidence, distribution, and prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) over the last 30 years and analyze changes over time.

Methods: All patients diagnosed with GEP-NETs in Iceland from 1985 to 2014 were identified through the Icelandic Cancer Registry and pathology laboratory records. Relevant clinical information was obtained from medical records. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/00365521.2018.1
Publisher Site
http://dx.doi.org/10.1080/00365521.2018.1553061DOI Listing
January 2019
4 Reads

Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review.

BMC Cancer 2019 Jan 11;19(1):52. Epub 2019 Jan 11.

Department of Oral & Maxillofacial Surgery, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Background: Cancers of unknown primary origin (CUPs) are reported to be the 3-4th most common causes of cancer death. Recent years have seen advances in mutational analysis and genomics profiling. These advances could improve accuracy of diagnosis of CUPs and might improve the prognosis of patients with CUPs. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-019-5277-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329170PMC
January 2019
6 Reads

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.

Br J Cancer 2019 Jan 23;120(2):141-153. Epub 2018 Dec 23.

The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK.

Cancers of Unknown Primary (CUP) comprise a heterogeneous clinical entity of confirmed metastatic cancer where the primary site of origin is undetectable. It has a poor prognosis with limited treatment options. CUP is historically under-researched; however, understanding its biology has the potential to not only improve treatment and survival by implementation of biomarkers for patient management, but also to greatly contribute to our understanding of carcinogenesis and metastasis across all cancer types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0332-2DOI Listing
January 2019
2 Reads

Palliative Radiotherapy as a Treatment for Carcinoma Invasion of the Sacrum: An Observational Case Series Study.

Anticancer Res 2018 Dec;38(12):6797-6800

Departments of Radiology, Neurology and Surgery, Louisiana State University Health Sciences Center, Shreveport, LA, U.S.A.

Background/aim: Radiotherapy for carcinoma invasion of the sacrum (CIS) is an alternative treatment to surgery in patients with advanced, inoperable tumors or those not medically eligible for resection of the neoplasm. Herein we present an observational study of patients with imaging-confirmed CIS who were treated non-operatively with radiation.

Patients And Methods: A retrospective chart review of CIS patients treated with palliative radiotherapy (PR) during a 9-year period (2004-2013) was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13051DOI Listing
December 2018
1 Read

BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells.

Sci Rep 2018 Dec 4;8(1):17608. Epub 2018 Dec 4.

Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242-1109, USA.

Bone marrow stromal antigen 2 (BST-2) mediates various facets of cancer progression and metastasis. Here, we show that BST-2 is linked to poor survival in invasive breast cancer patients as its expression positively correlates with disease severity. However, the mechanisms that drive the pro-metastatic functions of BST-2 are not fully understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35710-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279795PMC
December 2018

Utility of FNAC in Dermatological Manifestations of Metastatic Cancer with the Review of the Literature.

J Cytol 2018 Oct-Dec;35(4):237-241

Department of Surgery, Maulana Azad Medical College, New Delhi, India.

Objectives: Cutaneous metastasis (CM) though rare, indicates a terminal event in any malignancy and has a grave outcome. The present study reiterates the role of fine needle aspiration cytology (FNAC) in the diagnosis of metastatic cutaneous nodules.

Materials And Methods: From 2015 to 2017, the department received 22,000 cases for FNAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JOC.JOC_158_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210811PMC
December 2018

A Case of Mediastinal Lymph Node Carcinoma of Unknown Primary Site.

Tokai J Exp Clin Med 2018 Dec 20;43(4):148-152. Epub 2018 Dec 20.

Division of General Thoracic Surgery, Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan:

A 63-year-old man was pointed out with a mediastinal tumor on chest computed tomography (CT). On positron emission tomography-CT, fluorodeoxyglucose accumulation with a maximum standardized uptake value of 12.70 was seen in this tumor. Read More

View Article

Download full-text PDF

Source
December 2018
8 Reads

Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario.

Curr Oncol 2018 Oct 31;25(5):307-316. Epub 2018 Oct 31.

Department of Epidemiology and Biostatistics, Western University, London, ON.

Introduction: Patients with cancer of unknown primary (cup) have pathologically confirmed metastatic tumours with unidentifiable primary tumours. Currently, very little is known about the relationship between the treatment of patients with cup and their survival outcomes. Thus, we compared oncologic treatment and survival outcomes for patients in Ontario with cup against those for a cohort of patients with metastatic cancer of known primary site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209558PMC
October 2018
7 Reads

Tongue base mucosectomy for carcinoma of unknown primary using endoscopic electrocautery: rationale for wider implementation of an institutionally restricted technique.

J Laryngol Otol 2018 Dec 20;132(12):1138-1142. Epub 2018 Nov 20.

Department of ENT, Head and Neck Surgery,Royal Sussex County Hospital,Brighton, and Head and Neck Unit,Queen Victoria Hospital,East Grinstead,UK.

Background: Cervical metastasis from an unknown primary site invariably results in pan-mucosal irradiation if a primary tumour is not identified. Transoral robotic and laser-assisted mucosectomy are valid techniques to increase diagnostic rates, but these remain restricted to certain centres. This paper describes, in detail, a technique in which mucosectomy is performed via endoscopic electrocautery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0022215118002062DOI Listing
December 2018
18 Reads

Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma.

Cold Spring Harb Mol Case Stud 2018 Dec 17;4(6). Epub 2018 Dec 17.

Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia V5Z 4S6, Canada.

Thyroid-like follicular renal cell carcinoma (TLFRCC) is a rare cancer with few reports of metastatic disease. Little is known regarding genomic characteristics and therapeutic targets. We present the clinical, pathologic, genomic, and transcriptomic analyses of a case of a 27-yr-old male with TLFRCC who presented initially with bone metastases of unknown primary. Read More

View Article

Download full-text PDF

Source
http://molecularcasestudies.cshlp.org/lookup/doi/10.1101/mcs
Publisher Site
http://dx.doi.org/10.1101/mcs.a003137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318773PMC
December 2018
14 Reads

Transoral Robotic Surgery and the Unknown Primary.

ORL J Otorhinolaryngol Relat Spec 2018 12;80(3-4):148-155. Epub 2018 Nov 12.

University of Pittsburgh, Department of Otolaryngology, Eye & Ear Institute, Veterans Affairs Pittsburgh Health System, Pittsburgh, Pennsylvania, USA.

Carcinoma of unknown primary (CUP) comprises approximately 1%-5% of all head and neck malignancies. Primary site detection rates for metastatic cervical squamous cell carcinoma (SCC) remain variable, with current diagnostic imaging unable to identify all tumours. Prevailing evidence suggests that most head and neck CUP are located in the oropharynx. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/490596
Publisher Site
http://dx.doi.org/10.1159/000490596DOI Listing
November 2018
7 Reads

Incisional Seeding of Metastatic Squamous Cell Carcinoma Following Carotid Endarterectomy: An Unusual Case of an Unknown Primary Cancer Presenting as a Presumed Neck Abscess.

Oper Neurosurg (Hagerstown) 2018 Nov 10. Epub 2018 Nov 10.

Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, Ontario, Canada.

Background: Carotid endarterectomy (CEA) is a safe and effective procedure, with a low risk of complications when performed by experienced surgeons. Postoperative infections are particularly rare, reportedly affecting less than 1% of cases. Incisional metastases have not been described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ons/opy335DOI Listing
November 2018
3 Reads

A nomogram to predict long-time survival for patients with M1 diseases of esophageal cancer.

J Cancer 2018 11;9(21):3986-3990. Epub 2018 Oct 11.

Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University. 241 West Huaihai Road, Shanghai, 200030, China.

To evaluate the clinicopathologic characteristics of the long-time survivals and construct a clinical nomogram using the Surveilance, Epidemiology, and End Results (SEER) database. Information of patients diagnosed with M1 stage esophageal cancer from 2010-2014 was retrieved from SEER database. Patients with unknown information of AJCC TNM stage or metastatic sites or marital status or surgery or survival were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.27579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218766PMC
October 2018

Liquid biopsy: a new diagnostic, predictive and prognostic window in cancers of unknown primary.

Eur J Cancer 2018 Dec 30;105:28-32. Epub 2018 Oct 30.

University of Ioannina, Ioannina, Greece.

Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers characterised by early dissemination of metastases in the absence of any identifiable primary site. Most patients with CUP have poor prognosis with the traditional diagnostic and treatment modalities. Recognising the putative primary tumour is hypothesised to ameliorate the prognosis of patients with CUP by guiding treatment decisions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.09.035DOI Listing
December 2018
16 Reads

Spontaneous regression of lung squamous cell carcinoma with synchronous mediastinal progression: A case report.

Thorac Cancer 2018 Dec 11;9(12):1778-1781. Epub 2018 Oct 11.

Division of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

Spontaneous regression (SR) of cancer implies the partial or complete disappearance of malignant disease without or with adequate medical treatment. Typically, SR of cancer is a sporadic event, especially in non-small cell lung cancer (NSCLC). Although the underlying mechanism of SR remains unknown, stimulation of an immunological response has been proposed. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1759-7714.12892
Publisher Site
http://dx.doi.org/10.1111/1759-7714.12892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275820PMC
December 2018
25 Reads

Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).

Tissue Cell 2018 Oct 14;54:144-149. Epub 2018 Sep 14.

AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address:

Cancer of unknown primary (CUP) is metastatic disease without a known primary and therefore very difficult to identify effective therapy. Previously, we demonstrated partial efficacy of Salmonella typhimurium A1-R (S. typhimurium A1-R) alone and carboplatinum alone (CAR) on a CUP patient tumor in the patient-derived xenograft (PDOX) model. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00408166183030
Publisher Site
http://dx.doi.org/10.1016/j.tice.2018.09.001DOI Listing
October 2018
2 Reads

Metastatic squamous cell cancer with unknown primary origin in the mediastinal lymph node.

Authors:
M Agca A Kosif

Niger J Clin Pract 2018 Oct;21(10):1384-1386

Department of Thoracic Surgery, University of Health Sciences Istanbul Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey.

Metastatic tumors with unknown primary origin are a group of heterogeneous tumors with undetectable primary tumor site on admission. They have the common properties of rapid and aggressive progression and unpredictable metastases. They form 3%-5% of all cases with cancer and the fourth-most common cause of cancer-related deaths. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/njcp.njcp_149_18DOI Listing
October 2018
1 Read

Rare Case Report of Neuroendocrine Tumor in Axilla-Metastasis from Unknown Primary or De Novo?

Indian J Surg Oncol 2018 Sep 7;9(3):340-342. Epub 2017 Nov 7.

3HOD Surgical Oncology Department, Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, India.

Neuroendocrine tumors (NET) are the neoplasm arising from neuroendocrine cells which are present throughout the body. It can be benign, being more common or malignant. Gut is the most common site, but they can be seen in any part of the body. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13193-017-0716-4
Publisher Site
http://dx.doi.org/10.1007/s13193-017-0716-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154362PMC
September 2018
1 Read

Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.

Clin Genitourin Cancer 2019 Feb 28;17(1):e32-e37. Epub 2018 Aug 28.

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. Electronic address:

Background: Carcinoma of unknown primary site (CUP) is a heterogenous group of metastatic cancer with no detectable primary tumor site. Diagnostic assessment occasionally presents CUP with metastatic renal-cell carcinoma (mRCC) histologic and immunohistochemical characteristics (CUP-mRCC). Efficacy and toxicity data for vascular endothelial growth factor inhibitor therapies in CUP-mRCC patients are few. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.08.005DOI Listing
February 2019
2 Reads

Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine.

Am Soc Clin Oncol Educ Book 2018 May(38):20-25

From the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/EDBK_100014
Publisher Site
http://dx.doi.org/10.1200/EDBK_100014DOI Listing
May 2018
2 Reads

Combination of panendoscopy and positron emission tomography/computed tomography increases detection of unknown primary head and neck carcinoma.

Laryngoscope 2018 Nov 8;128(11):2573-2575. Epub 2018 Sep 8.

Department of Facial Plastic and Reconstructive Surgery , Otolaryngology and Facial Plastic Surgery Associates, Fort Worth, Texas, U.S.A.

Objectives/hypothesis: With positron emission tomography/computed tomography (PET/CT) now commonplace as a diagnostic tool, new questions have arisen regarding the utility and cost-effectiveness of panendoscopy. In this retrospective review of a large cohort of head and neck squamous cell carcinoma of unknown primary (HNSCC-UP), we describe the enduring utility of panendoscopy in the detection of the primary site of mucosal disease even when PET/CT is negative.

Study Design: Retrospective cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lary.27268DOI Listing
November 2018
12 Reads

Minimal Increase in Survival Throughout the Years in Patients with Soft Tissue Sarcoma with Synchronous Metastases: Results of a Population-Based Study.

Oncologist 2018 Sep 6. Epub 2018 Sep 6.

Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Background: Treatment options for patients with metastatic soft tissue sarcoma (STS) have increased in the last decade. We aimed to examine whether this is associated with improved overall survival (OS) in patients with STS with synchronous metastases.

Patients And Methods: Patients diagnosed with STS and synchronous metastases from 1989 to 2014 were queried from The Netherlands Cancer Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0383DOI Listing
September 2018
8 Reads

Evaluation of Carcinoma of Unknown Primary on Cytologic Specimens.

Surg Pathol Clin 2018 Sep;11(3):545-562

Department of Pathology, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

Carcinoma of unknown primary is defined as metastatic carcinoma without a clinically obvious primary tumor. Determining the tissue of origin in carcinoma of unknown primary is important for site-directed therapy. Immunohistochemistry is the most widely used tool for the work-up of metastases, but molecular profiling assays are also available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2018.04.006DOI Listing
September 2018
3 Reads

Searching for the Culprit: Metastases from a Cancer of Unknown Primary.

Case Rep Oncol 2018 May-Aug;11(2):541-548. Epub 2018 Aug 10.

Oncology Research Unit, Médica Sur Hospital and Clinical Foundation, Mexico City, Mexico.

We report a case of metastases from a cancer of unknown primary whose primary site could not be identified during the appropriate pretreatment evaluation. The patient was a 58-year-old woman with a history of passive smoking and with no history of cancer in the family. Her current condition started with asthenia, adynamia, and pallor, followed by palpitations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120367PMC
August 2018
1 Read

Liver metastasis of a neuroendocrine neoplasm of unknown primary origin in a female patient with a history of breast cancer.

Contemp Oncol (Pozn) 2018 29;22(2):124-128. Epub 2018 Jun 29.

Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.

We report on and discuss a case of a female patient diagnosed with breast cancer in 1996, which was histopathologically assessed as an invasive ductal carcinoma. The patient was admitted to our Department in 2017 with a liver metastasis of a neuroendocrine tumour. On admission she had no symptoms of an endo-crinopathy and was in a good general condition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2018.76831DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103232PMC
June 2018
1 Read

Diffuse Bone Marrow Metastasis as the Initial Presentation of an Occult Breast Cancer.

Case Rep Oncol Med 2018 22;2018:2946409. Epub 2018 Jul 22.

Department of Radiology, Changhua Hospital, Ministry of Health and Welfare, Chang-Hua County, Taiwan.

Introduction: Breast cancer is one of the malignancies which tend to involve the bone marrow, but initial presentation with diffuse bone marrow metastasis from an occult breast cancer is very rare. Prognosis is generally very poor for marrow metastasis from solid tumors except that breast cancer is a treatable disease even in such a dismal condition.

Case: A 64-year-old woman's headache was found to result from diffuse adenocarcinoma metastasis in the bone marrow from an unknown primary site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/2946409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081566PMC
July 2018
2 Reads

Epithelial-myoepithelial carcinoma: a population-based survival analysis.

Authors:
Mitchell R Gore

BMC Ear Nose Throat Disord 2018 16;18:15. Epub 2018 Aug 16.

Department of Otolaryngology, SUNY Upstate Medical University, Physicians Office Building North, Suite 4P, 4900 Broad Road, Syracuse, NY 13215 USA.

Background: Epithelial-myoepithelial carcinoma is an uncommon malignant neoplasm seen most frequently in the salivary glands, representing approximately 1 to 2% of salivary gland tumors. Less than 600 cases have been reported in the literature since its initial description in 1972. The aim of this study was to examine demographic, site, stage, and survival factors in patients with epithelial-myoepithelial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12901-018-0063-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097440PMC

Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin.

Middle East Afr J Ophthalmol 2018 Apr-Jun;25(2):81-90

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Purpose: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site.

Methods: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site.

Results: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/meajo.MEAJO_6_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071342PMC
September 2018
7 Reads

Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience.

South Asian J Cancer 2018 Jul-Sep;7(3):207-209

Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India.

Background: Neuroendocrine carcinoma (NEC) is a rare tumor arising from the diffuse neuroendocrine system. Most of these present in the advanced stage and palliative chemotherapy remains the only option. The prognosis remains poor with the standard chemotherapy regimen of platinum and etoposide (EP) providing modest survival benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_176_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069343PMC
August 2018
2 Reads

Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination Interleukin-8.

Front Immunol 2018 30;9:1767. Epub 2018 Jul 30.

Department of Oncology, Linköping University, Linköping, Sweden.

Fat is a major tissue component in human breast cancer (BC). Whether breast adipocytes (BAd) affect early stages of BC metastasis is yet unknown. BC progression is dependent on angiogenesis and inflammation, and interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) are key regulators of these events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077262PMC
July 2018
1 Read

Solid malignant metastases in the jaw bones.

Br J Oral Maxillofac Surg 2018 Oct 6;56(8):705-708. Epub 2018 Aug 6.

Croatian National Institute of Public Health, Zagreb, Rockefellerova 7, Croatia.

Metastatic tumours to the jaw bones are rare, and usually develop during the final stages of cancer. Some, such as those of lung, breast, and kidney, are more likely to metastasise to the jaw. We have therefore analysed the clinical and epidemiological characteristics of patients with metastatic tumours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bjoms.2018.07.013DOI Listing
October 2018

Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.

Gynecol Oncol 2018 09 25;150(3):527-533. Epub 2018 Jul 25.

Prince of Wales Clinical School, Faculty of Medicine, UNSW Sydney, NSW, Australia; Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia.

Objective: Advanced stage mucinous ovarian cancers are diagnostically and therapeutically challenging. Histotype specific trials have failed due to low recruitment after excluding non-ovarian primaries. Mucinous ovarian cancers are commonly metastatic from other sites however lack definitive diagnostic markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.07.013DOI Listing
September 2018
3 Reads

[Bilateral Metastatic Lung Tumor with Different Primary Organs].

Kyobu Geka 2018 Jun;71(6):430-433

Department of Surgery, Onomichi Municipal Hospital, Onomichi, Japan.

A 72-year-old woman with a history of surgery for left breast cancer was found to have sigmoid colon cancer and solitary pulmonary tumor of left upper lobe. We diagnosed adenocarcinoma of the unknown origin by a transbronchial biopsy. We performed left upper segmentectomy and sigmoidectomy. Read More

View Article

Download full-text PDF

Source
June 2018
1 Read

Unknown primary carcinoma in the Netherlands: decrease in incidence and survival times remain poor between 2000 and 2012.

Eur J Cancer 2018 Sep 20;101:77-86. Epub 2018 Jul 20.

Comprehensive Cancer Organisation the Netherlands, Department of Research, Utrecht, The Netherlands; Department of Public Health, Erasmus MC University Medical Center Rotterdam, The Netherlands.

Background/aim: Unknown primary tumour (UPT) is the term applied to metastatic cancer, the origin of which remains unidentified. Since cancer treatment is primarily based on the tumour site of origin, treatment of UPT patients is challenging. The number of reports on incidence, treatment and survival of UPT is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.06.032DOI Listing
September 2018
11 Reads

Metastatic breast cancer simulating well-differentiated neuroendocrine neoplasms of visceral organs.

Hum Pathol 2018 Dec 18;82:76-86. Epub 2018 Jul 18.

Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore 21231-2410, MD, USA; Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore 21231-2410, MD, USA. Electronic address:

A series of metastatic breast carcinoma (MBC) mimicking visceral well-differentiated neuroendocrine neoplasms has not previously been reported. We identified 5 consultation cases originally submitted as neuroendocrine neoplasms in women but that were found to be MBC on subsequent review. All 5 neoplasms demonstrated nested architecture and relatively uniform nuclei. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00468177183026
Publisher Site
http://dx.doi.org/10.1016/j.humpath.2018.07.011DOI Listing
December 2018
3 Reads

[Clinical Practice of Carcinoma of Unknown Primary].

Gan To Kagaku Ryoho 2018 Jun;45(6):891-893

Division of Breast and Medical Oncology, National Cancer Center Hospital East.

Carcinoma of unknown primary(CUP)is defined as the presence of metastatic cancer documented in the absence of an identifiable primary tumor site. According to this definition, between 1% and 5% of cancer patients are diagnosed with this clinical entity. CUPs are a heterogeneous group of neoplasms with widely varying natural histories and biologic characteristics. Read More

View Article

Download full-text PDF

Source

The Evaluation of Cutaneous Metastasis from an Unknown Primary.

J Drugs Dermatol 2018 Jul;17(7):804-806

We present the case of a man that had a rapidly growing nodule on his face. Removal of the lesion was more difficult than anticipated because it was tightly adherent to adjacent tissue. Pathology from the lesion showed a malignant neoplasm thought to have arisen at a distant site. Read More

View Article

Download full-text PDF

Source
July 2018
5 Reads

Diagnostic accuracy of contrast-enhanced computed tomography for assessment of mandibular and medial retropharyngeal lymph node metastasis in dogs with oral and nasal cancer.

Vet Comp Oncol 2018 Dec 10;16(4):562-570. Epub 2018 Jul 10.

Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida.

The diagnostic accuracy of contrast-enhanced CT for detection of cervical lymph node metastasis in dogs is unknown. The purpose of this retrospective, observational, diagnostic accuracy study was to assess the efficacy of CT for detection of mandibular and medial retropharyngeal lymph node metastasis in dogs. Histopathology of dogs with cancer of the head, CT and bilateral mandibular and medial retropharyngeal lymphadenectomy was reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vco.12415DOI Listing
December 2018
1 Read

Metastatic squamous cell carcinoma with pseudoangiosarcomatous features and aberrant expression of vascular markers.

Pathol Res Pract 2018 Oct 12;214(10):1732-1737. Epub 2018 Jun 12.

Duke University Medical Center, Department of Pathology, Durham, NC, United States. Electronic address:

Squamous cell carcinoma with pseudoangiosarcomatous features is a rare but well-recognized variant of squamous cell carcinoma. These tumors exhibit complex anastomosing channels lined by neoplastic cells, histologically mimicking a vasoformative mesenchymal tumor. Immunohistochemically, the published cases expressed epithelial markers and were consistently negative for vascular markers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2018.06.006DOI Listing
October 2018
8 Reads

SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.

APMIS 2018 Jun;126(6):494-500

Institute of Pathology, Regional Hospital Randers, Randers, Denmark.

CDX2 is routinely used for identifying gastrointestinal origin of metastatic adenocarcinomas; but a high percentage of other carcinomas also show positivity with this antibody. SATB2 is a new immunohistochemical marker with a few studies showing that it is specifically expressed in a large majority of colorectal adenocarcinomas. We assessed SATB2 along with CDX2 in patient material with metastasis in order to determine whether the primary site could be identified as 'colon-rectum'. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/apm.12854
Publisher Site
http://dx.doi.org/10.1111/apm.12854DOI Listing
June 2018
17 Reads

Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary.

J Comp Eff Res 2018 Jun 1;7(6):523-533. Epub 2018 Jun 1.

Foundation Medicine Inc., Cambridge, MA 02141, USA.

Aim: Time to treatment and pretreatment costs may be affected by unknown primary tumor site.

Methods: This retrospective study used electronic medical record data from patients in ten US community oncology practices. Eligible patients were ≥18 years, diagnosed with cancer of unknown primary (CUP) or known metastatic solid tumor, and presented between 1 January 2012 and 30 June 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/cer-2017-0104DOI Listing

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.

Clin Transl Oncol 2018 Nov 28;20(11):1361-1372. Epub 2018 May 28.

Pathology Department, Hospital Universitario Arnau de Vilanova de Lleida y Hospital Universitari de Bellvitge, IRBLLEIDA, IDIBELL, CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain.

Cancer of unknown primary (CUP) is defined as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They differ from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-018-1899-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182632PMC
November 2018

[Clinical significance of four quadrant localization in the diagnosis and treatment of metastatic carcinoma of the neck with unknown primary].

Authors:
Y Y Gao X H Chen

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017 Jun;31(11):858-862

Department of Otolaryngology Head and Neck Surgery, Affiliated Beijing Tongren Hospital of Capital Medical University.

The aim of this study is to investigate the clinical significance of four quadrant localization in the diagnosis and treatment of unknown primary cervical metastases. The clinical data with unknown primary cervical metastases, were analyzed retrospectively. All the patients have not been found the original site in the initial treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.13201/j.issn.1001-1781.2017.11.010DOI Listing

[Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].

Hinyokika Kiyo 2018 Apr;64(4):187-192

The Department of Urology, Japanese Red Cross Society Wakayama Medical Center.

An 84-year-old man was referred to our hospital with swollen right cervical lymph nodes. Computed tomography showed right supraclavicular and mediastinal lymph node enlargement, and fluorodeoxyglucose positronemissiontomography showed multiple areas of abnormally increased radioactivity inthe right supraclavicular and mediastinal lymph nodes, right ninth rib, and left fifth and seventh ribs. Biopsy of the right supraclavicular lymph node revealed metastatic adenocarcinoma with partial immunohistochemical staining for prostate specific antigen (PSA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14989/ActaUrolJap_64_4_187DOI Listing
April 2018
4 Reads

Role of 18F-FDG PET/CT in patients without known primary malignancy with skeletal lesions suspicious for cancer metastasis.

PLoS One 2018 10;13(5):e0196808. Epub 2018 May 10.

Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Background: When subjects without a known malignancy present with suspicious skeletal lesions, differential diagnosis and primary cancer identification is important. Here, we investigated the role of FDG PET/CT in this clinical situation.

Methods: We enrolled 103 patients with no known malignancies who were referred for FDG PET/CT because of bone lesions that were suspicious for cancer metastasis. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196808PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945029PMC
August 2018
4 Reads

Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.

J Med Case Rep 2018 May 6;12(1):122. Epub 2018 May 6.

Department of Pathology, Ministry of Health and Welfare Changhua Hospital, Chang-Hua County, Taiwan, Republic of China.

Background: Definite diagnosis of metastasis from unknown primary depends on a comprehensive immunohistochemical investigation of tumor specimen. Accurate identification of the origin site usually helps a lot in choosing the most appropriate treatment. Molecular characterization provides more chance of a cure. Read More

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1674-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5936624PMC
May 2018
12 Reads

Cutaneous and Subcutaneous Metastases of Adenocarcinoma as a Dominant Clinical Manifestation of Malignancy of Unknown Origin - a Case Report.

Klin Onkol 2018 ;31(2):143-147

Background: Cutaneous metastases occur in 0.6-10.4% of all patients with underlying malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14735/amko2018143DOI Listing
January 2018
2 Reads